Result: We also screened several mutations relevant to antiviral resistance, such as I169L, L180M, A181V, T184I, S202C, M204V/I, N236T and M250I in the RT region.
Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
PMID: 28316253
2017
AIDS research and human retroviruses
Abstract: Five subjects had rtV173L, rtL180M, and rtM204V and one with rtL180M and rtM204V major mutations.
HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Discussion: Following TDF therapy, the frequencies of rtM204I and rtL80I were found to decrease in both responders and non-responders although there was little change in the prevalence of rtM204V and rtL180M.
Discussion: Our results further extended these previous findings and raised doubts about the effectiveness of TDF
Discussion: documented that HBV bearing the rtM204V + rtL180M mutations displayed a 3.33 and 2.1-fold increase in the IC50 for TDF compared to wild-type virus in cell culture suggesting that TDF was less efficacious on these LMV-resistant mutants.
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
Abstract: Seven patients (14.9%) exhibited genotypic resistance mutations (M204I +/- L180M) during the virologic breakthrough.
Result: Of these patients, genotypic resistance mutations to Telbivudine (M204I +/- L180M) were detected in seven during the virologic breakthrough.
Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).
PMID: 28017671
2017
Journal of global antimicrobial resistance
Abstract: M204I, N236T and L180M+M204V+V173L/S202G were the most common substitutions for l-nucleoside (3TC and LdT), ADV and ETV genotypic resistant phenotypes, respectively.
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Abstract: Despite the finding that rtL180M and rtM204V/I were higher among ART-experienced individuals, the overall prevalence of DRMs (48.0% versus 36.4%) showed no significance difference among antiretroviral therapy (ART) status.
Abstract: Lamivudine selected DRMs, that is, rtL180M (29.3%) and rtM204V/I (29.3%) and rtV173L (15.5%) were more prevalent in HBV-HIV-coinfected individuals but absent in HBV-monoinfected individuals.
Abstract: RESULTS: In 34 out of 161 study subjects (21.1%) HBV drug resistance mutations (DRM
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Abstract: The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173L, rtL180M and rtM204V mutations.
Discussion: Although there were differences in genotype, the dominant pattern of resistance among treatment-experienced patients with mutated strains, (rtM204V + rtL180M), was similar between the European multi-center study (29%) and the present study in Ghana (47.6%).
Discussion: In our study, twenty (95.2%) of the 21
Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
PMID: 27313669
2016
Experimental and therapeutic medicine
Abstract: At the initiation of sequential monotherapy with ADV, LAM-resistant variants (rtM204V/I and rtL180M) were detected in the three patients.
Abstract: During 30-41 months of ADV-ETV combination therapy, viral load reduction was 2.59-3.28 log10 copies/ml; ADV-resistant variants rtA181T/V and rtN236T were undetectable following 11-24 months of combination therapy; and rtL180M and rtM204I/V remained dominant in the viral population.
Abstract: In conclusion, the results of the present study suggested that, in patients with LAM and ADV-resista
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.
Abstract: RESULTS: TDF susceptibilities of lamivudine-resistant clones (rtL180M/M204V) and lamivudine plus entecavir-resistant clones (rtL180M/S202G/M204V) were similar to wild type clones in vitro.
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Abstract: Treatment with lamivudine resulted in an increased rate of the viral mutations, rtM204V/I, rtL180M and rtL80I.
Result: In all four patients, the M204V mutation was accompanied by the L180M m
Discussion: Additionally, the present study revealed that YVDD-variant-dominated virological breakthrough was closely associated with the L180M mutation, and an identical trend in the changes of the M204V and L180M mutations was observed, which raised the question of the specific mechanism of rt204 and its supplementary sites.
HBV mutation literature information.
PMID: 
2017
Emerging microbes & infections
Browser Board
Co-occurred Entities
Filtrator
ViMRT